Orthopediatrics stock hits 15-minute chart MACD death cross and Bollinger bands narrowing.

The 15-minute chart of Orthopediatrics has recently triggered a MACD Death Cross, accompanied by Bollinger Bands Narrowing at 08/07/2025 15:15. This indicates that the stock price has the potential to continue declining, with the magnitude of fluctuations decreasing.

Orthopediatrics (KIDS) reported its fiscal 2025 Q2 earnings on August 6, 2025, delivering a strong revenue increase but posting wider losses. The company’s performance fell short of profitability expectations, though it raised full-year revenue guidance earlier in the quarter. Revenue climbed 15.7% to $61.08 million, with the Trauma and Deformity segment leading the growth with $41.66 million, followed by the Scoliosis segment at $18.52 million. However, losses widened to $0.30 per share, marking the 11th consecutive annual loss [1].

Shares of Orthopediatrics have faced downward pressure, with a 9.64% decline on the latest trading day, a 17.44% drop over the past week, and a 15.73% loss month-to-date. A post-earnings strategy of buying KIDS shares after a revenue increase and holding for 30 days proved highly unprofitable, returning -60.79% over the past three years [1].

The 15-minute chart of Orthopediatrics has recently triggered a MACD Death Cross, accompanied by Bollinger Bands Narrowing at 08/07/2025 15:15. This indicates that the stock price has the potential to continue declining, with the magnitude of fluctuations decreasing [2]. Analysts have been cautious about Orthopediatrics' outlook, with Jefferies maintaining a Hold rating on the stock, citing potential access challenges and competition from AstraZeneca (NASDAQ: AZN) [2].

Orthopediatrics has been making strategic moves to strengthen its market position. On August 5, 2025, the company announced the continued expansion of its Specialty Bracing division into new territories with multiple clinics, underscoring its commitment to broadening its orthopedic solutions. Additionally, the company reported a 58% year-over-year increase in adjusted EBITDA and raised full-year 2025 revenue guidance [1].

Management raised full-year 2025 revenue guidance to $237 million to $242 million, representing year-over-year growth of 16% to 18%. Gross margin guidance remains at 72% to 73%. Adjusted EBITDA is expected to be between $15 million and $17 million. The company continues to expect its first quarter of positive free cash flow in Q4 2025 and free cash flow breakeven for the full year 2026 [3].

Investors should closely monitor Orthopediatrics' regulatory pathway discussions with the FDA and any potential partnering announcements, as these events could influence the stock's performance. The company's ability to navigate regulatory challenges and maintain market share gains will be crucial for its long-term success.

References:
[1] https://www.ainvest.com/news/orthopediatrics-2025-q2-earnings-misses-profitability-revenue-grows-2508/
[2] https://www.ainvest.com/news/orthopediatrics-15min-chart-shows-bollinger-bands-narrowing-kdj-death-cross-2508/
[3] https://seekingalpha.com/news/4479430-orthopediatrics-raises-2025-revenue-outlook-to-237m-242m-amid-accelerated-opsb-clinic